Article metrics

Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study


Online download statistics by month:

Online download statistics by month: April 2021 to January 2022

Apr 202139236494
May 202113412754
Jun 202111811841
Jul 202114814523
Aug 2021727122
Sep 2021626318
Oct 2021313231
Nov 2021242326
Dec 2021272613
Jan 2022231710